Study of Molecular Test for Lung Cancer

A new molecular test that detects altered autoimmunity and associated patterns is to be used in a new clinical study for the detection of lung cancer.

The test, called CellCorrect Lab test, was developed by CeMines, Inc. (Golden, CO, USA). The study, to be conducted by Colorado Heart & Body Imaging, LLC (CHBI, Denver, CO, USA), will relate patient serum biomarkers and imaging in diverse and healthy population groups.

CeMines expects its test to detect altered autoimmunity and associated patterns of autoantibodies in the bloodstream related to lung cancer. The company uses a proprietary bioinformatics, pattern-recognition platform called Molecular FingerPrinting. Extensive cancer biomarker libraries are used to evaluate not only the presence or absence of autoantibody markers but have been further developed to detect patterns of specific antibodies useful in profiling cancers.

"Physicians today have very limited choices of minimally invasive testing as a tool for use in diagnosis of lung cancer at an earlier stage,” explained Roger Attick, CEO of CeMines. "The alliance between CeMines and CHBI has the potential to create a ‘best in class' diagnostic protocol. When evaluated with CHBI advanced imaging, CellCorrect Lab blood testing based on CeMines Molecular FingerPrinting provides complementary physiological data, thus enabling CHBI physicians to be more precise in analysis of anomalies detected during cardio-pulmonary imaging.”

"I am confident that early detection efforts, combining electron beam tomographic (EBT) imaging with CellCorrect Lab specific serum biomarkers, should favorably change the prognosis for thousands,” stated James Ehrlich, M.D., medical director and founder of CHBI.





Related Links:
CeMines
CHBI